A Phase 4 interventional study of Mirikizumab in Lactation and Inflammatory Bowel Disease, sponsored by Eli Lilly and Company. Recruiting at 20 sites in 7 countries. Open to female participants aged 3 Weeks and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Breast Feeding with a site in United States — 44 open to participants now, 49 under way, none of them phase 3. Breast Feeding · United States.
Among the 251 studies in Breast Feeding with a site in United States, this one is the 168th largest by planned enrollment of the 202 interventional ones that give a count, is one of 14 that started in 2026, is one of 14 in phase 4, reaches primary completion later than 35 of the 48 other live ones, and was the 244th registered.
1,082 studies on the registry are indexed under Breast Feeding; 217 are open to participants now.
Browse Breast Feeding studies →44 of the 251 studies in Breast Feeding with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+ · Women only
University of Illinois at Urbana-Champaign · Sites in United States
Ages 21–45 · Women only · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18–50 · Women only
University of Colorado, Denver · Sites in United States
Women only · Healthy volunteers
Loma Linda University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 127 Breast Feeding studies recruiting now, 66 (52%) set no upper age limit and 59 (46%) stop at 75 or younger; 53 take children under 18; 76 take healthy volunteers.
This study: 3 Weeks and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 10 · Phase 3 6 · Phase 4 14
First in 2000; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 14 is below the median of 100 across 845 interventional studies indexed under Breast Feeding.
Median enrollment 83 across the 202 interventional studies, 88 across the 49 observational. Of the 180 that completed or were terminated, 46 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 251 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 1 study filed under Breast Feeding — fewer than ten, so there is no comparison to draw.
15 of the studies in Breast Feeding with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07176793University of California, DavisPregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes | 2026-12-30 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT06107933Johns Hopkins Bloomberg School of Public HealthDevelopmental Impacts of Microplastics Exposure in Early Life | 2026-12-31 |
| NCT05441709Endeavor HealthFurthering Equity Through Infant Feeding EDucation and Support | 2026-12-31 |
| NCT03838536University of North Carolina, Chapel HillSynergistic Activity of Human Milk Nutrients and Infant Cognition | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 251 studies in Breast Feeding with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the amount of mirikizumab in breast milk in women who are breastfeeding who are receiving stable maintenance doses of mirikizumab for an approved indication.
Participation in this study could last up to 94 days, including screening and follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study Participants:
Note: in the opinion of the healthcare practitioner (HCP), there are no infant or maternal issues that would preclude the mother participant or the infant from participation
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will continue to use previously prescribed Mirikizumab administered subcutaneously (SC).
Drug: Mirikizumab
Administered SC
Also known as: LY3074828
Concentration of Mirikizumab in Breast Milk
Time frame: Predose up to 28 Days
Pharmacokinetic (PK): Average Concentration During a Dosing Interval in Steady State of Mirikizumab in Breast Milk
Time frame: Predose up to 28 Days
Pharmacokinetic (PK): Area Under the Concentration Versus Time Curve Over a Dosing Interval [AUC(0-tau)] of Mirikizumab in Breast Milk
Time frame: Predose up to 28 Days
Breastfed Infant Safety as Assessed through Measurement of Infant Weight
Time frame: Predose up to 28 Days
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Sep 2028, 25 months after the start.
Of 17 phase 4 interventional studies under Breast Feeding, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 25 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab